Long non-coding RNAs in osteosarcoma

Abstract

Long non-coding RNAs (lncRNAs) with more than 200 nuleotides, have been explored to participate in various cancer types including osteosarcoma (OS), which is the most common kind of primary bone tumors with high morbidity in infants and adolescents. These oncogenic or tumor suppressive lncRNAs regulate OS pathogenesis, such as cell growth, proliferation, invasion, migration, metastasis and cell apoptosis, serve as independent prognostic biomarkers or play a significant role in multidrug resistance (MDR) in OS cells. In this review, we attempt to dissect the participation of lncRNAs in pathogenesis of OS and their potential clinical values, and also provide an outlook for viable biomarkers and therapeutic targets in OS.

LncRNA SOX2‐OT is a novel prognostic biomarker for osteosarcoma patients and regulates osteosarcoma cells proliferation and motility through modulating SOX2

“…Long noncoding RNAs (lncRNAs) are a class of non‐protein‐coding molecules longer than 200 nucleotides that are involved in the development and progression of human cancers including osteosarcomas . In the past few years, many lncRNAs have been shown to be an oncogene or antioncogene such as TUG1 , ZEB1‐AS1 , SPRY4‐IT1 , H19 , BCAR4 , and MFI2 .…”

Overexpression of Long Non-Coding RNA NNT-AS1 Correlates with Tumor Progression and Poor Prognosis in Osteosarcoma

“…Even though more and more lncRNAs have been reported to play crucial roles in osteosarcoma [15, 17, 21], the roles of lncRNAs in osteosarcoma are remain poorly defined. The identification of osteosarcoma-associated lncRNAs was needed to better understand the initiation and progression of osteosarcoma.…”

“…Increasing evidence indicates that lncRNAs interact with nucleic acids or proteins in diverse biological processes, including cell proliferation, cell differentiation, chromatin remodeling, and drug resistance [9-11]. Previous studies have shown that lncRNAs could act as oncogenes or tumor suppressors during the development and progression of cancers, such as hepatocellular carcinoma, lung cancer, pancreatic cancer, osteosarcoma, and colon cancer [12-17]. For example, lncRNA DGCR5 was decreased in hepatocellular carcinoma tissues and serum, and low DGCR5 expression was associated with HbsAg and vascular invasion.…”

Prognostic value of abnormally expressed long non-coding RNAs in patients with osteosarcoma: a meta-analysis

“…These potential biomarkers predictive of survival or response to therapy will be helpful to guiding the individualized treatment of osteosarcoma patients and finally improve their outcome. In recent years, studies have demonstrated that lncRNAs are involved in various biological processes of osteosarcoma, including progression and metastasis, and aberrant expression of multiple lncRNAs was found to have the potential value for predicting outcome of osteosarcoma patients [37,38].…”